These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 24568915)

  • 1. [Effect of parent training in combination with methylphenidate treatment on family relationships for children with attention deficit/hyperactivity disorder].
    Zhang Y; Kang CY; Zhao XR; Xuan X; Ding KJ; Liu RX; Wang YJ; Yang RX; Li XR; Wan S
    Zhongguo Dang Dai Er Ke Za Zhi; 2014 Feb; 16(2):185-9. PubMed ID: 24568915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parental quality of life and depressive mood following methylphenidate treatment of children with attention-deficit hyperactivity disorder.
    Kim Y; Kim B; Chang JS; Kim BN; Cho SC; Hwang JW
    Psychiatry Clin Neurosci; 2014 Jul; 68(7):506-14. PubMed ID: 24417707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylphenidate-osmotic-controlled release oral delivery system treatment reduces parenting stress in parents of children and adolescents with attention-deficit/hyperactivity disorder.
    Hwang JW; Kim B; Kim Y; Kim TH; Seo WS; Shin DW; Woo YJ; Yoo H; Lee JS; Lee JH; Lim MH; Chung YC; Jung CH; Yoo HK
    Hum Psychopharmacol; 2013 Nov; 28(6):600-7. PubMed ID: 24519694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health-related quality of life in methylphenidate-treated children with attention-deficit-hyperactivity disorder: results from a Taiwanese sample.
    Yang P; Hsu HY; Chiou SS; Chao MC
    Aust N Z J Psychiatry; 2007 Dec; 41(12):998-1004. PubMed ID: 17999272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A pilot study of methylphenidate and parent training in the treatment of children with attention-deficit hiperactivity disorder].
    Montiel Nava C; Peña JA; Espina Mariñes G; Ferrer-Hernandez ME; López-Rubio A; Puertas-Sánchez S; Cardozo-Durán JJ
    Rev Neurol; 2002 Aug 1-15; 35(3):201-5. PubMed ID: 12235578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder.
    Klassen AF; Miller A; Fine S
    Pediatrics; 2004 Nov; 114(5):e541-7. PubMed ID: 15520087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parent-reported executive function behaviors and clinician ratings of attention-deficit/hyperactivity disorder symptoms in children treated with lisdexamfetamine dimesylate.
    Findling RL; Adeyi B; Dirks B; Babcock T; Scheckner B; Lasser R; DeLeon A; Ginsberg LD
    J Child Adolesc Psychopharmacol; 2013 Feb; 23(1):28-35. PubMed ID: 23410139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The adolescent outcome of children with attention deficit hyperactivity disorder treated with methylphenidate or methylphenidate combined with multimodal behaviour therapy: results of a naturalistic follow-up study.
    van der Oord S; Prins PJ; Oosterlaan J; Emmelkamp PM
    Clin Psychol Psychother; 2012; 19(3):270-8. PubMed ID: 21404369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder.
    Polanczyk G; Zeni C; Genro JP; Guimarães AP; Roman T; Hutz MH; Rohde LA
    Arch Gen Psychiatry; 2007 Feb; 64(2):218-24. PubMed ID: 17283289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study.
    Biederman J; Swanson JM; Wigal SB; Kratochvil CJ; Boellner SW; Earl CQ; Jiang J; Greenhill L
    Pediatrics; 2005 Dec; 116(6):e777-84. PubMed ID: 16322134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Empathy and Facial Expression Recognition in Children With and Without Attention-Deficit/Hyperactivity Disorder: Effects of Stimulant Medication on Empathic Skills in Children with Attention-Deficit/Hyperactivity Disorder.
    Gumustas F; Yilmaz I; Yulaf Y; Gokce S; Sabuncuoglu O
    J Child Adolesc Psychopharmacol; 2017 Jun; 27(5):433-439. PubMed ID: 28332851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Behavioral parent training as an adjunct to routine care in children with attention-deficit/hyperactivity disorder: moderators of treatment response.
    van den Hoofdakker BJ; Nauta MH; van der Veen-Mulders L; Sytema S; Emmelkamp PM; Minderaa RB; Hoekstra PJ
    J Pediatr Psychol; 2010 Apr; 35(3):317-26. PubMed ID: 19633060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of combined treatment on Turkish children diagnosed with attention-deficit/hyperactivity disorder: a preliminary report.
    Ercan ES; Varan A; Deniz U
    J Child Adolesc Psychopharmacol; 2005 Apr; 15(2):203-19. PubMed ID: 15910205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ginkgo biloba for attention-deficit/hyperactivity disorder in children and adolescents: a double blind, randomized controlled trial.
    Salehi B; Imani R; Mohammadi MR; Fallah J; Mohammadi M; Ghanizadeh A; Tasviechi AA; Vossoughi A; Rezazadeh SA; Akhondzadeh S
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb; 34(1):76-80. PubMed ID: 19815048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Catechol-O-methyltransferase valine158methionine polymorphism moderates methylphenidate effects on oppositional symptoms in boys with attention-deficit/hyperactivity disorder.
    Salatino-Oliveira A; Genro JP; Zeni C; Polanczyk GV; Chazan R; Guimarães AP; Callegari-Jacques SM; Rohde LA; Hutz MH
    Biol Psychiatry; 2011 Aug; 70(3):216-21. PubMed ID: 21550019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
    Chou WJ; Chou MC; Tzang RF; Hsu YC; Gau SS; Chen SJ; Wu YY; Huang YF; Liang HY; Cheng H
    Psychiatry Clin Neurosci; 2009 Apr; 63(2):167-75. PubMed ID: 19335386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline severity of parent-perceived inattentiveness is predictive of the difference between subjective and objective methylphenidate responses in children with attention-deficit/hyperactivity disorder.
    Park S; Kim BN; Cho SC; Kim JW; Shin MS; Yoo HJ; Han DH; Cheong JH
    J Child Adolesc Psychopharmacol; 2013 Aug; 23(6):410-4. PubMed ID: 23952188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of methylphenidate on subtypes of attention-deficit/hyperactivity disorder.
    Gorman EB; Klorman R; Thatcher JE; Borgstedt AD
    J Am Acad Child Adolesc Psychiatry; 2006 Jul; 45(7):808-16. PubMed ID: 16832317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A process for developing community consensus regarding the diagnosis and management of attention-deficit/hyperactivity disorder.
    Foy JM; Earls MF
    Pediatrics; 2005 Jan; 115(1):e97-104. PubMed ID: 15629972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.